Annual Results Presentation for the year ended 30 June 2024 -- 1 of 75 -- 2 Normalised operating profit Core new business +18% to R26 667m +17% to R11 604m Normalised headline earnings +15% to R7 329m Headline earnings +7% to R7 202m Total income from non-insurance +16% to R6 191m FY24 performance overview Excluding discontinued products like VitalityInvest and DBI and Ping An Health reinsurance business Discovery Insure Discovery Life Discovery Invest Discovery Bank Discovery Health Vitality Limited Vitality Health Vitality Life Vitality Network Vitality Health International -- 2 of 75 -- 3 Slow but steady economic recovery Moderate GDP growth Slowing inflation Outlook High interest rates Inflation rate by market1 Central bank policy rates2 1 Sources: StatsSA, Statista, Office for National Statistics, US Bureau of Labor Statistics 2 Source: Bank of International Settlements Global • Declining global inflation • Accommodative financial conditions • Stable growth expected • Geopolitical tensions persist with elections in major economies South Africa • Stabilising interest rates • Moderating inflation; consumer pressure remains • Economic green shoots post-GNU United Kingdom • NHS challenges persist • Modest growth; falling inflation continues • Recovering consumer spending China • Strained West relations • GDP growth expected to reach 5% in 2024 • Stabilising exports from global manufacturing recovery • Accommodative policy expected United States • Recession fears due to slowing growth and cooling jobs market • Falling inflation; Fed commenced cutting rates • Elevated geopolitical risk from volatile politics 0% 1% 2% 3% 4% 5% 6% 7% 8% 9% Jan-20 Jul-20 Jan-21 Jul-21 Jan-22 Jul-22 Jan-23 Jul-23 Jan-24 Jul-24 South Africa United Kingdom China United States -2% 0% 2% 4% 6% 8% 10% 12% Jun-20 Dec-20 Jun-21 Dec-21 Jun-22 Dec-22 Jun-23 Dec-23 Jun-24 United States South Africa China United Kingdom 0% 1% 2% 3% 4% 5% 6% 7% 8% 9% 2021 2022 2023 2024f 2025f World United Sates Euro area China South Africa -- 3 of 75 -- 4 Focus areas Entering a new phase in the lifecycle of the Group 1 2 3 Strong FY24 performance Delivering on business-specific performance Creating two distinct businesses with significant ambition and a common business model 4 -- 4 of 75 -- 5 FY24 Performance -- 5 of 75 -- 6 Strong operating performance Health 3 972 +7% 11 069 +26% 1 260 +5% Life 4 765 +9% 2 942 +4% Invest 1 522 +20% 3 300 +8% Insure 248 +240% 1 388 +11% Bank -454 -41% 2 102 +39% Other SA1 -336 +20% 1 038 +38% SA 9 717 +16% 19 737 +19% 3 362 +24% Vitality Health 435 -47% 2 488 +21% Vitality Life 375 -20% 1 956 +14% UK initiatives -163 -70% UK 647 -14% 4 444 +17% Vitality Network 533 +30% 1 894 +16% VHI - Ping An Health 1 124 +85% 2 486 +14% 935 -6% VHI - Other -386 +98% VG initiatives -31 -11% VG 1 240 +57% 2 486 +14% 2 829 +8% Operating profit New business2 1 Vitality, Other SA Initiatives and Group initiatives and central costs 2 Excl products in run down Non-insurance incomeZARm +17% R11 604m +18% R26 667m +16% R6 191m -- 6 of 75 -- 7 40% 50% 60% 70% 80% FY19 FY20 FY21 FY22 FY23 FY24 12% 14% 16% 18% 20% 22% 24% 26% 28% 30% FY22 FY23 FY24 0% CSM 50% CSM 100% CSM Group well capitalised with robust cash generation FLR decreasing Strongly capitalised Improving cash conversion Sufficient centre liquidity DHMS solvency (unaudited) 30% 1 Capital Adequacy Ratio 2 Comprehensive Solvency Ratio, definition set by China Banking and Insurance Regulatory Commission 3 Centre cash + undrawn committed facilities 4 Normalised for COVID-19 reserve impact 28% 23% 20% 17% FLR Jun 23 Cover Jun 24 Cover Life 1.8x 1.8x Insure 1.6x 1.6x VH 1.4x 1.6x VL 2.1x 2.0x Bank1 1.3x 1.3x PAHI2 2.7x 3.2x Group cash conversion4 Centre liquidity3, Rm 66% - 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500 R4.1bn (R1.5bn of which to be used to repay maturing debt by Nov 2024) -- 7 of 75 -- 8 Strong growth in Group Embedded Value Opening EV Value of new business Unwind of risk discount rate Non-economic experience variances and methodology & assumption changes Operational EV Economic experience variances and methodology & assumption changes Non-Covered Businesses Forex Finance Costs, Investment Income & Other Change in Captial & Dividends Closing EV R113 439m R98 176m R110 354m 13.2% Annualised RoEV -- 8 of 75 -- 9 Below the line affected by swaption in prior period Rm 12 months ended 12 months ended % Jun-24 Jun-23 Normalised profit from operations 11 604 9 917 17% Forex losses/gains -87 150 1 DP financing lease impact -105 -134 Investment income and fair value gains on financial instruments 480 354 Finance charges excl. 1DP finance lease -1 750 -1 628 Other -131 -117 Profit before fair value gains on VL swaption 10 011 8 543 17% Fair value gains on VL swaption 516 Profit before tax 10 011 9 059 11% Tax -2 647 -2 486 Profit not attributable to ordinary shareholders -206 -174 Loss on impairment and derecognition 48 257 Other headline earnings adjustments -4 65 Headline earnings 7 202 6 720 7% Fair value gains on VL swaption 0 -410 Other 127 90 Normalised headline earnings 7 329 6 400 15% Fair value gains: prior period includes a considerable fair value gain from the swaption held in DHEL, which was realised towards the end of the previous financial year Forex losses/gains: ZAR closing rates strengthened compared to opening rates resulting in losses on translation of GBP and USD currency accounts and loans receivable. In the prior year, the closing rates weakened resulting in a foreign translation gain Loss on impairment and derecognition: Largely attributable to write-off of assets resulting from wind-down of VitalityCar and assets no longer in use in VitalityHealth Final dividend declaration of 152cps in respect of FY24 -- 9 of 75 -- 10 Entering a new phase of growth Past Today Future Highly cash generative with superior growth. Maintaining leadership in SA with the Bank scaling; and a material international business Pioneering and globalising the Vitality shared-value model; substantial investment in new initiatives for organic growth Reduced spend and streamlined new initiatives; key initiatives maturing; transitioned to IFRS 17 -- 10 of 75 -- 11 The new phase of growth should have a positive impact on financial metrics Average Where we were (FY16-FY23) Where we are today (FY24) Where we are headed (FY25-FY29) Earnings growth 9% CAGR 17% 15-20% CAGR % spend on New 15% (maxed at 25%) 8% c5% Cash conversion 56% 66% 60-70% RoE 13% 13% 15-20% FLR 22% 20% 10-20% Dividend cover 5.7x 5x <5x Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors -- 11 of 75 -- 12 Strong operating profit performance Operating profit, Rm - 2,000 4,000 6,000 8,000 10,000 12,000 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 IFRS 17 IFRS 4 COVID-19 -- 12 of 75 -- 13 Three distinct phases Operating profit by phase of growth, Rm - 2,000 4,000 6,000 8,000 10,000 12,000 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Big investments in New Unfettered organic growth CAGR 9.1% CAGR 22.3% 15-20% p.a. Scaled organic growth (FY25-FY29) Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors -- 13 of 75 -- 14 Growth dynamics of the operating and business model Organic growth engine Vitality shared-value business model Upfront selection Persistency Claims Consistent value drivers across the business yielding superior outcomes relative to traditional insurance books LIFE HEALTH INSURE Profitability 17% Claims savings from initial selection 7% Claims reduction from initial selection 23% Good drivers self-selecting 42% Lower lapses 20% Lower lapses 64% Lower lapses 9% Claims reduction 13% Claims reduction 58% Claim severity reduction Community- rated and not for profit 12% Higher VNB margin 17% Lower loss ratios Profitability ESTABLISHED EMERGING NEW CPI + 5% CPI + 30% -10% Aim for Group to be on the growth curve -- 14 of 75 -- 15 Entering a new phase of growth % spend on new Dividend cover Cash conversion (normalised history) Operating profit growth FLR RoE Going forward: scaled organic growth 15-20% RoE 15-20% CAGR c5% Spend on new 10-20% FLR <5x Dividend cover 60-70% Cash conversion -20% 0% 20% 40% 0% 10% 20% 30% 0% 10% 20% 30% 0% 50% 0 0.2 0.4 - 2 4 6 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 Big investments in New Unfettered organic growth Illustrative ranges Average 13% Average 20% Average 22% Average 3% 4.6x 5.7x CAGR IFRS 4 9% CAGR 22% 8% 15% 56% 60% Average Average Average Average Average Average 13% 20% 5x 17% 8% 66% Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors and reflects the average expected over the time frame R14.5bn in the Bank -- 15 of 75 -- 16 The new phase should result in an improving central cash position Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors Improving cash conversion Cash conversion Reducing demand for cash from the centre Cash from the centre, Rm Vitality Global - 500 1,000 1,500 2,000 2,500 3,000 FY19 FY20 FY21 FY22 FY23 FY24 FY25-FY29 - 500 1,000 1,500 2,000 2,500 3,000 FY19 FY20 FY21 FY22 FY23 FY24 FY25-FY29 - 500 1,000 1,500 2,000 2,500 3,000 FY19 FY20 FY21 FY22 FY23 FY24 FY25-FY29 - 500 1,000 1,500 2,000 2,500 3,000 FY19 FY20 FY21 FY22 FY23 FY24 FY25-FY29 PAHI capital injection R376m FY19-FY24 R2.5bn FY19-FY24 R2.7bn FY19-FY24 R8.3bn FY19-FY24 40% 50% 60% 70% 80% 66% Decreasing spend on New initiatives 0% 5% 10% 15% 20% 25% 30% 10% % earnings on new R0m R0m R0m cR500m -- 16 of 75 -- 17 Well positioned for future growth Expect continued organic growth Profitability Inherent organic growth from Bank and Vitality Limited: 12.5% to 17.5% average earnings growth p.a. (FY25-FY29) 20% to 30% average earnings growth p.a. (FY25-FY29) Discovery Group Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors -- 17 of 75 -- 18 The effect of behaviour change exceeds expectations Physical activity has a significant impact on mortality and increases by age Physical activity has a significant impact on healthcare costs -29% -52% -59% 0 (base) Low Medium High -36% -38% -58% 0 (base) Low Medium High Relative mortality for the 45-65 age group Relative mortality for the 65+ age group Relative reduction for the 45-65 age group Relative reduction for the 65+ age group -16% -25% No Habit Strong poor habit Strong good habit -14% -29% No Habit Strong poor habit Strong good habit No habit Strong poor habit Strong good habit No habit Strong poor habit Strong good habit Effects of behaviour change increase with age and chronicity Young moderately healthy 30-year-old 10.2 56.7 43.5 53.7 Healthspan Sick years 10 46.7 Middle age unhealthy 50-year-old 10 .2 16.6 24.9 Healthspan Sick years 25.1 Advanced age unhealthy 70-year-old 4 14.6 6.1 10.1 Healthspan Sick years 11.6 +7% increase in healthspan +51% increase in healthspan +90% increase in healthspan 8.3 33.5 8.4 3 -- 18 of 75 -- 19 Evolving the shared- value model to engage members in a personalised programme -- 19 of 75 -- 20 Creating two distinct businesses with significant ambition and a common business model Limited -- 20 of 75 -- 21 Consolidating Vitality UK and Vitality Global to achieve two clear composites with competitive advantage Leading financial services group in SA via the consistent application of the Vitality Shared-value Insurance model, ensuring every business is a market leader in its category and integrates with other businesses in the Group to benefit customers; and a best-in-class bank that enables the composite via its unique payment systems, ecosystems and shared currency Leading international insurance group that revolutionises insurance through the scaling of the Vitality Shared-value Insurance model, utilising the UK – and the institutional structure and strength of its insurance businesses – as the centre of excellence and epicentre for R&D, together with partnerships with the best insurers globally Ambition: Ambition: -- 21 of 75 -- 22 Discovery SA -- 22 of 75 -- 23 -- 23 of 75 -- 24 Discovery Bank Revenue (NII + NIR) Retail deposits Advances Operating result Total accounts Total clients +41% to (R454m) +89% to (R52m) Before NBAC +36% +40% to >950k to 2.3m +29% +27% to R18.5bn to R6.6bn +41% to R2.1bn H1 2023 H2 2023 H1 2024 H2 2024 NBAC Loss before NBAC 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 Total NII Total NIR Total Accounts Total Clients -- 24 of 75 -- 25 Strong and quality new business growth from multiple sources Accelerating growth in sales Relevance across demographic groups Majority new to Discovery 1,271 - 200 400 600 800 1,000 1,200 1,400 Aug-21 Nov-21 Feb-22 May-22 Aug-22 Nov-22 Feb-23 May-23 Aug-23 Nov-23 Feb-24 May-24 ±1,100 sales per day Number of other Discovery products 58% of new business is new to Discovery 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 0 1 2 3 4+ 0% 10% 20% 30% 40% Credit card new business by income #1 market share in affluent, and one of the leading banks in mass affluent New business by age group High share of new business from young adults 0% 10% 20% 30% 40% 18-24 25-34 35-44 45-54 55-65 65+ SA population 3-month moving average; per business day -- 25 of 75 -- 26 Maintained focus on credit book growth and quality 1 Market average Credit Loss Ratio based on the latest results of the top 5 banks in South Africa Strong growth in advances book Promising home loans book and pipeline Better than market credit losses driven SVM 100% 27% 12% 7% 3% Blue Bronze Silver Gold Diamond Credit loss ratio by VM status 0 1 2 3 4 5 6 7 Jul-22 Aug-22 Sep-22 Oct-22 Nov-22 Dec-22 Jan-23 Feb-23 Mar-23 Apr-23 May-23 Jun-23 Jul-23 Aug-23 Sep-23 Oct-23 Nov-23 Dec-23 Jan-24 Feb-24 Mar-24 Apr-24 May-24 Jun-25 +27% Value of home loans disbursed, Rm Advances, Rbn Credit loss ratio vs market1 +3.4% 96 617 17 521 149 132 New Loan Switch Total 113 653 766 Loans Disbursed Approved - legal finalisation 0% 2% 4% 6% 8% Jun-21 Jun-22 Jun-23 Jun-24 Market average Discovery CLR TTC -- 26 of 75 -- 27 Established market leadership Best in retail banking Best in private banking Best bank brand driven by disruptive products and superior service Top private banking provider Best relationships with clients Best service and experience metrics Best emotional experience Smart, simple and easy products Excellent benefits and rewards -- 27 of 75 -- 28 Declining costs-to-serve leading to operational breakeven Note: Jaws graph indexed to October 2023. New clients and NBAC per client graphs indexed to Q1 FY22 Positive jaws from cost vs income Strong operating profit with H2 breakeven Stable NBAC per client as the bank grows -600 -500 -400 -300 -200 -100 0 100 200 H1 2022 H2 2022 H1 2023 H2 2023 H1 2024 H2 2024 Loss before NBAC NBAC H2 Breakeven 40 60 80 100 120 140 Jul-22 Sep-22 Nov-22 Jan-23 Mar-23 May-23 Jul-23 Sep-23 Nov-23 Jan-24 Mar-24 May-24 Cost pc Avg net income pc Reaching breakeven earlier than expected Profit before NBAC, Rm -60 -40 -20 0 20 40 60 80 100 Jul-23 Oct-23 Jan-24 Apr-24 Jul-24 Oct-24 Jan-25 Apr-25 Jul-25 Oct-25 2023 Expectations Current Expectations Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors 0 50 100 150 200 250 Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Cumulative acquisition cost per client New clients -- 28 of 75 -- 29 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 High quality bank with bold goals Attributes driving growth Capital invested, Rm R14.5bn (nominal) Reducing capital needs Projection Capital requirements based on the Bank segmental projections Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors Driven by bold ambition R400m operating profit growth p.a. Targeting 2m clients and R3bn in profits in FY29 1 High-quality clients • ±50% credit, suite and transaction bundled 2 Deposit-led growth • Advances to Deposits ratio less than 40%; deposit growth rate is 7% higher than the advances growth rate providing a strong funding position • +15% above FY24 target 3 NIR-driven income • ±8% growth in average net income per client from FY23 to FY24 resulting in 45% NIR growth 4 Operational scalability • Cost-to-Income ratio improvement by ±15% from FY23 to FY24 5 Optimised profitability • 89% growth in profit/loss before NBAC between FY23 and FY24 -- 29 of 75 -- 30 -- 30 of 75 -- 31 Discovery Health *Sasolmed contributed R2 510m to new business for FY2024 Operating profit New business Non-scheme growth Membership +7% +26% >3.9m to R3 972m to R11 069m* Lives under administration 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 >370k lives +16% Jan-18 Aug-18 Mar-19 Oct-19 May-20 Dec-20 Jul-21 Feb-22 Sep-22 Apr-23 Nov-23 Jun-24 Flexicare Gap Cover Healthy Company 1993 1996 1999 2002 2005 2008 2011 2014 2017 2020 2023 Non Scheme Products Restricted Schemes DHMS -- 31 of 75 -- 32 0% 5% 10% 15% 20% 25% 30% 35% 40% 0 5 10 15 20 25 30 35 2019-20 2020-21 2021-22 2022-23 2023-24 Reserve Actual Solvency Required Solvency 0% 2% 4% 6% 8% 10% 2019-20 2020-21 2021-22 2022-23 2023-24 0% 1% 2% 3% 2019-20 2020-21 2021-22 2022-23 2023-24 Upgrades Downgrades Discovery Health Medical Scheme: continued excellent performance in a complex environment Membership and market share as at June 2024 Plan changes exclude impact of plan closures Membership Customer satisfaction Solvency 57.9% market share Low proportions of members change plans, with more members upgrading than downgrading: Lapses continue to remain stable R28.4bn 30% AAA projected unaudited reserves projected unaudited solvency credit rating R billion 96% no plan changes DHMS Rest of the industry Others -- 32 of 75 -- 33 High utilisation driving medical inflation Overall medical inflation Tariffs Supply side utilisation Risk mngt, Vitality effect & efficiencies Demand side utilisation + 4.8% + 2.5% Net: 7.4% to 10.9% + 1.9% to 5.4% – 1.8% Increased ageing of the scheme contributes 47% to the demand side utilisation 1 Demand side utilisation ranges from 1.9% to 5.4% depending on the plan type, with an average of 4.1% Increasing chronicity accounts for 15% of the demand side utilisation* 2 The buy-down effect & plan mix contributes 38% to the demand side utilisation 3 Over the last 10 years, c39% of demand side impact is due to adverse selection Chronic beneficiaries have grown from 15.8% in 2008 to 33.1% in 2024 *The increasing chronicity captures the increased chronic prevalence over and above what is expected due to the increased aging -- 33 of 75 -- 34 Discovery Health actively addressing the issues of an ageing scheme and increasing chronicity Attracting young professionals Addressing chronicity -13% -16%-18% -16% -14% -12% -10% -8% -6% -4% -2% 0% Clinical habits Physical activity habits -16% -18%-20% -18% -16% -14% -12% -10% -8% -6% -4% -2% 0% Clinical habits Physical activity habits Relative in-hospital cost reduction moving from poor to strong habit Relative mortality reduction moving from poor to strong habit Rich rewards through Vitality & Vitality Active 25% OFF Healthy food 75% OFF Gym membership FULLY FUNDED Fitness device 24 FREE VISITS At other fitness facilities Introducing ACTIVE SMART Most affordable plan at R1,350 per month -- 34 of 75 -- 35 Additional tax revenue assumed by NDoH is not sustainable NHI scenario relies on R200bn additional tax revenue 2,332 407 714 Current private medical schemes Current funding for uncovered lives Current NHI proposal Healthcare cost (ZAR) Post Pre Economic growth would enable greater social spending Required additional annual GDP growth over a 20-year period 0% 2% 4% 6% 8% 10% 12% 50 100 200 300 400 500 600 700 800 900 1000 Additional GDP growth required Additional Tax Revenue Rbn Retail Reduction in profit margins Including efficiencies DoH estimate Primary care, extended chronic, maternity, PMB hospital Extended hospital+specialist 7.2% 10.4% 8.6% R200bn Additional funding required per annum, as indicated by the National Department of Health 31% increase in personal income tax or; 6.5% increase in VAT (from 15% to 21.5%) or; 10x increase in payroll tax (current UIF contributions) -- 35 of 75 -- 36 Section 33 is the pinch point to allowing private sector collaboration; there are a number of other complex and critical areas in the act 33. Once National Health Insurance has been fully implemented as determined by the Minister through regulations in the Gazette, medical schemes may only offer complementary cover to services not reimbursable by the Fund. 1. Until the NHI is fully implemented, there are no restrictions on medical schemes 2. When it is fully implemented, complementary cover may be added – key question: how comprehensive will NHI be? -- 36 of 75 -- 37 -- 37 of 75 -- 38 Discovery Life Normalised operating profit New business Maintained leading market share Strong capital and liquidity 2020 2021 2022 2023 2024 Individual Group IFRS 17 +9% to R4 765m Individual life: +11% 2020 2021 2022 2023 2024 Individual Group SCR coverage Liquidity coverage 2024 2024 183% R5 446m 1 X ILT 125% SCR Target +4% to R2 942m Individual life: +4% 2023 2024 12 months to June 2024 27.3%27.1% -- 38 of 75 -- 39 Strong EV growth and improvement in VNB margin Strong cashflow generation Improvement in VNB margin Operating variances Strong EV growth Life and Invest cashflow in excess of 35% of net of tax normalised earnings Jun23 Margin Business mix Non-economic assumptions Economic assumptions Jun24 Margin VNB margin (%) 2.54% 3.80% 19.3% IRR Business mix and expenses Jun-22 New Business Expected unwind incl New Business Experience Variances Methodology and Assumption Changes Total before Economic Impact Experience Variances Methodology and Assumption Changes Components below the line Jun-23 R41 138m R45 948m R47 519m Non- economic +15.5% Economic +11.7% Jun -24 Jun -23 Expected unwind Other (including dividends) +14.3% RoEV Discovery Life Ltd variances, Rm Mortality and morbidity Persistency Premium and fee income Policy alterations Other Total non-economic Economic Total R114m -R40m Largely offsetting 3.2%* *Individual Life 5.0%* 2021 2022 2023 2024 CF before financing Financing repaid Cashflows before financing R1 960m R2 260m -R765m -R638m Covid impact Net change in financing Impact of basis change: R1.2bn on EV, R2.8bn on balance sheet -- 39 of 75 -- 40 % Growth +7.1% +8.7% -7.0% = c9% Expected growth at current new business rates Actual value generation of business under IFRS 17 1 Represented by DSY and competitor CSM balances rebased to the same starting level for comparative purposes; 2 SA Life and Invest (risk) portfolio; 3 SA Life Segment IFRS 17 stored margin absorbs basis change2 Stable earnings growth3 New business Insurance finance income / expense Release to earnings Variances and basis changes Other Equal offset to release of margins -55 2,674 -474 2,061 559 New business Variances and basis changes Release to earnings CSM 23,423 RA 6,348 OCI -5,264 24,507 23,499 2,787 2,110 -5,128 -2,061 2,784 -1,500 OCI -3,980 CSM 20,237 RA 7,242 Economic margin Non -economic margin June 2023 June 2024 Net impact of - -R2.3bn 6% of PVFCF of corresponding business Insurance finance income / expense Comparative non-economic margin1 runoff excl new business Positive margin dynamics 1 2 3 4 5 6 7 8 9 10 CSM Balance (rebased) Projection Year Competitor 1 Competitor 2 Competitor 3 SA Life and Invest GMM 28,264 OCI -3,980 CSM 20,237 RA 7,242 In-period earnings 4,765 Store of value at start of period plays out as earnings during the period plus store of value at end of period (Rm) Total current and future value -- 40 of 75 -- 41 -- 41 of 75 -- 42 2020 2021 2022 2023 2024 Once-off items Discovery Invest Normalised operating profit New business Positive shift in product mix Assets under administration +20% +8% +11% to R1 522m to R3 300m to R155bn 2020 2021 2022 2023 2024 +12% IFRS 17 Jan-17 Sep-17 May-18 Jan-19 Sep-19 May-20 Jan-21 Sep-21 May-22 Jan-23 Sep-23 May-24 % AuM in offshore funds 0% 5% 10% 15% 20% 25% 30% 35% 40% Feb-22 May-22 Aug-22 Nov-22 Feb-23 May-23 Aug-23 Nov-23 Feb-24 May-24 Rebased profit release profile (guaranteed bonds) -- 42 of 75 -- 43 -- 43 of 75 -- 44 Discovery Insure 1 Prior years have been restated to exclude vehicles that remain on Discovery Insure's books without cover during the Gap in Cover period Gross written premium Gross new business Normalised operating profit Vehicles insured1 +9% +11% +240% +2% to R5 726m to R1 388m to R248m to 288 120 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 H1 21 H2 21 H1 22 H2 22 H1 23 H2 23 H1 24 H2 24 IFRS 17 -- 44 of 75 -- 45 Vitality Car Rating underpinned by rich dataset, enabling an opportunity to disrupt the second-hand vehicle market Driving and telematics data linked longitudinally Insure’s longitudinal view of a vehicle provides richer insights than traditional cross-sectional view Leveraging complex actuarial modelling to measure value Kilometres of driving data collected since inception 20bn Driving events detected each day 800k Average number of cars going for panel beating p.a. 54k Vehicle claims received in FY2024 93k General dealerships Discovery Insure VEHICLE DETAILS • Vehicle make and model • Service history in DI • Vehicle assessment • What the vehicle is used for • Speeding by power-to-weight • Region • Cold starts • Time spent in sun • Distance travelled • % of city vs highway driving • Average trip speed • Number of trips • Average trip distance • Road surface quality • Accidents split by cosmetic, mechanical, structural • Repairer, repair details, warranties on parts • Detailed accident history: frequency, severity, geolocation, impact alert. • Driving profile - speeding, cornering, acceleration, braking • Speed relative to power • Vertical oscillation • Vehicle make and model • Service history • Vehicle assessment • Distance travelled • Severity • Number of accidents NO INFO MILEAGE TYPE ACCIDENT INFO DRIVING STYLE Boost the vehicle resale value by up to 15% 8% Discovery Insure vehicles have a 5-star rating Over 300 dealerships, representing over 30 brands including: -- 45 of 75 -- 46 Hyper-personalisation and shared value with the Bank as the composite maker -- 46 of 75 -- 47 Personal Pathways manifesting on the face of the Bank -- 47 of 75 -- 48 Vitality Limited Vitality Limited Vitality Health Vitality Life Vitality Network Vitality Health International -- 48 of 75 -- 49 UK -- 49 of 75 -- 50 Highly rated Vitality UK has strong assets and attributes that position it for growth going forward Excellent service Strong brand Top employer Amongst the top ten ‘Best Places to Work: Very Big Organisation’s in The Sunday Times Awards 2024 307% growth in brand awareness, compared to 5% growth in market average Trustpilot (4.3/5) and app store ratings (4.9/5) Over 1.8 million lives Over £1.1 billion in premiums Jun-24 Jun-23 Jun-22 Jun-21 Jun-20 Jun-19 Jun-18 Jun-17 2019 2020 2021 2022 2023 2024 Unique brand collaborations with new partner, Itsu Over £180m in new business API 2019 2020 2021 2022 2023 2024 3rd largest health insurer and life term and CI writer Well-recognised mascot High engagement 250k Apple Watches; 100,000 ‘active’ gym members; 75% have actively registered on our Member Zone -- 50 of 75 -- 51 Health -- 51 of 75 -- 52 VitalityHealth 1 Excludes VitalityCar write-down in prior year Normalised operating profit1 Earned premiums New business Lives covered -52% +12% +10% +7% to £18.5m to £699.3m to £105.7m to 1m 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 IFRS 17 GBP millions GBP millions GBP millions +23% to R16.5bn +21% to R2.5bn -47% 2024 2023 2022 2021 2020 to R435m -- 52 of 75 -- 53 Pressure on the NHS is driving increased utilisation and costs of private healthcare The Darzi Review1 1 Poor NHS performance: Missing waiting time targets since 2015, waiting lists and times have surged 2 Concerns in quality of care: Areas of concern i.e maternity care. Cancer survival and cardiovascular disease mortality rates for people under 75 improvements have slowed substantially 3 NHS budget not being spent where it should be: Too great a share in hospitals, too little in the community, and productivity is too low 4 Low capital investment: The NHS has been starved of capital and the capital budget was repeatedly raided to plug holes in day-to-day spending. This has resulted in crumbling buildings that hit productivity. On top of this, there is a shortfall of £37m of capital investment 5 Disengaged staff: High levels of sickness absence following pandemic. Marked reduction in discretionary effort across all staff groups 6 Rise in bureaucratic processes: Regulatory type organisations now employ c7000 staff/ 35 per provider trust, having doubled in size over the past 20yrs 7 Improving the NHS will take time: Improving health service back to peak performance will take years. Unlikely waiting lists can be cleared and other performance standards restored in one parliamentary term 1 Source: UK government, 2 Source: NHS Digital: Referral to Treatment Waiting Times, 3 Source: Office of National Statistics Demand driven by NHS backlogs COVID-19 60% 80% 100% 120% 140% 160% 180% 200% Jun-18 Sep-18 Dec-18 Mar-19 Jun-19 Sep-19 Dec-19 Mar-20 Jun-20 Sep-20 Dec-20 Mar-21 Jun-21 Sep-21 Dec-21 Mar-22 Jun-22 Sep-22 Dec-22 Mar-23 Jun-23 Sep-23 Dec-23 Mar-24 Jun-24 NHS waiting list Authorisations per 1000 NHS waiting list2 and authorisations YoY change3 Doctor strikes Nurses strike -- 53 of 75 -- 54 95% 97% 99% 101% 103% 105% 107% 109% Jan Feb Mar Apr May Jun Jul Aug Premium PLPM Rolling 12m average Claims PLPM Pricing actions taken in line with market to restore margin, with retention remaining resilient Earned premiums expected to offset claims Stable lapse rates despite premium increases Positive retention of healthier lives Premiums and claims PLPM FY25 8% claims overrun in FY24 100% 96% 98% 90% 98% 2020 2021 2022 2023 2024 60% 70% 80% 90% 100% 110% 120% Bronze Silver Gold Platinum Lapse Rate index Invited increase index Average Individual and SME lapse rate (rebased) Lapse rate and invited rate increase by status -- 54 of 75 -- 55 Superior operating model positions VitalityHealth for growth 1 Source: LaingBuisson Health Cover Report 19th Edition; 2 Source: Health and Protection: Individual Private Medical Insurance Report, August 2024; 3 Source S.05 reporting within the SFCR’s published on our competitor’s websites, using latest available full year data 3rd largest health insurer Attracting healthier lives 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Bupa AXA Health VitalityHealth Aviva Market share by player1 Average age of individual PMI policyholders2 - 10 20 30 40 50 60 70 Aviva Axa VitalityHealth Increased claims ratios expected to stabilise Market vs VitalityHealth claims ratios3 61% 68% 67% 73% 53% 48% 51% 54% 58% 2020 2021 2022 2023 2024 Market excluding VH VitalityHealth -- 55 of 75 -- 56 Life -- 56 of 75 -- 57 VitalityLife Normalised operating profit Earned premiums New business Lives covered -27% +10% +4% +6% to £15.9m to £401.9m to £83.1m to 810k 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 IFRS 17 GBP millions GBP millions GBP millions +21% to R9.5bn +14% to R2.0bn -20% to R375m -- 57 of 75 -- 58 Robust underlying performance, with further action taken to manage PAC book Strong operating results before basis change Low margins on the PAC book Actions to position PAC book for stability Taken action to address key issues with the PAC and VLL books, and expect a smoother and stronger emergence of profits each year going forward PAC book generates substantial cash 80% 20% VLL PAC 10.4 318.7 14 62.6 PAC VLL CSM RA Policy count split between VLL and PAC (%) Margin balances in VLL and PAC, £m FY 23 profit Profit before basis changes Basis changes FY 24 profit +31% -27% 2022 Deferred Part VII transfer 2023 Reconfigured hedging strategy to align with IFRS 17 2024 Significant strengthening of basis for level-premium WOL business Changes to accounting policy to correctly reflect nature of PAC book, which will result in lower period on period volatility 0 5 10 15 20 25 30 35 40 FY 5 FY FY 7 FY 8 FY FY 0 FY FY FY FY 4 FY 5 PAC book net cashflow before reserving requirements, £m Operating profit, £m Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors -- 58 of 75 -- 59 Operating environment has been challenging, but changing dynamics provide opportunities Large, stagnant market; fundamentals improving The optimiser product has 3 unique product features 779 718 767 760 776 2019 2020 2021 2022 2023 Rich multi-benefit business is increasingly common in the market 4th largest life insurance market Market sales1, £m Optimiser provides dynamic discounts1 Significantly higher engagement on optimiser2 Optimiser drives better actuarial dynamics - retaining better risks and reducing claims 3 -49% None Low Medium High Claims by physical activity band -47% No Points Low Moderate High Lapse rate by physical activity Up to 30% lower premiums than standard rate 3x more engaged than non-optimised members 98% of advisers recommend products through portals, leading to commoditisation+20% 2019 2023 % of sales on a multi-benefit basis2 1 GenRe Protection Pulse, 2 NMG UK Distribution Insights -- 59 of 75 -- 60 Generating new business value through price optimisation Creates unique portal competitive advantage Enables higher rider benefit take-up Driving operational efficiencies A ‘tale of two halves’ Improved pricing sophistication & speed Optimised: Position 1 Non-Optimised: Position 9 Portal design encourages advisers to quote on other life insurance benefits Relative rider adoption +52% +150% Non- Optimised Optimised Optimiser customers have significantly higher benefit size and rider adoption Non- Optimised Optimised Average benefit size Utilising an optimisation loop that is underpinned by a rich & comprehensive dataset, with features unique to Vitality Strategic Action: Efficient Frontier We optimise Value Models Conversion Models 70% 71% 73% 77% Q1 Q2 Q3 Q4 STP Rate during FY24 77% of applications are now automatically decisioned 18% volume growth H2 on H1 + Improved profitability mix = £million H1 H2 FY24 New business APE 29.1 34.3 63.4 New business net value -0.5 16.6 16.1 VNB (£m) -5.7 0.3 -5.5 VL was up 11% H2 FY24 on H2 FY23 Wider UK protection market (excl VL) was down 4.5% during the period -- 60 of 75 -- 61 Actual value generation of business under IFRS 17 1 Represented by Vitality and competitor CSM balances rebased to the same starting level for comparative purposes IFRS 17 stored margin absorbs basis change Stable earnings growth % Growth Comparative non-economic margin1 runoff excl new business Positive margin dynamics Store of value at start of period plays out as earnings during the period plus store of value at end of period (GBPm) 1 2 3 4 5 6 7 8 9 10 11 CSM Balance (rebased) Projection Year Competitor 1 Competitor 2 Competitor 3 VitalityLife = -c2.5% expected growth p.a. before variances Economic margin New business Insurance finance income/ expense Variances and basis changes Release to earnings Non -economic margin June 2023 June 2024 CSM 366 RA 66 OCI 30 462 518 9 +4.5% 20 +2.0% -40 -9.0% -16 54 28 OCI 112 CSM 333 RA 73 H1: 1.5 H2: 18.3 Significantly improved new business margins in the second half New business Insurance finance income / expense Variances and basis changes Release to earnings Other Total current and future value -4 10 -24 40 -6 Equal offset to release of margins OCI 112 CSM 333 RA 73 In-period earnings 15.9 533 -- 61 of 75 -- 62 Network -- 62 of 75 -- 63 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 Vitality Network Integrated API by insurance partners Revenue Insurance partners membership Operating profit +11% to $1 575.1m +18% to R29.7bn +10% to $101.3m +16% to R1.9bn +23% to $28.5m +30% to R533m +17% to 5.3m 2020 2021 2022 2023 2024 USD millions USD millions USD millions 2020 2021 2022 2023 2024 -- 63 of 75 -- 64 Vitality Network’s globally expanding footprint -- 64 of 75 -- 65 Key strategic focus areas 1 Grow revenue through deepening of existing insurance partnerships and targeted pursuit of new insurance partnerships 2 Evolve Vitality products to drive greater value through utilisation of the science of hyper-personalisation 3 Unlock geared profits by significant revenue growth (through scaling) and maintaining a flat expense base +10% Revenue growth for FY2024 (USD) +23% Profit growth for FY2024 (USD) 19% 21% 21% 26% 25% 30% 2019 2020 2021 2022 2023 2024 Profit margin (excl. FX) Redeveloped the mobile architecture to support the incorporation of the habit index and hyper-personalisation, through physical activity and healthy actions Hosted partner- wide GVC, rolling out personalisation enhancements Revolutionised the mobile experience Expansion of strategic role of Vitality Stand Alone – focus on 2030 targets Driving VONB growth - focus on agent engagement -- 65 of 75 -- 66 The V1 Platform enhances Vitality Limited’s ability to expand globally 𝑞 𝑥+𝑡 𝑞 𝑥 𝑞 𝑥 | 𝑦 𝑞 𝑥+𝑡 | 𝑦 𝑞 𝑥+𝑡 𝑦 𝑧 Mortality rate Age Up to 31% Reduction in mortality* Value generated through engagement and formation of healthy habits Swiss Re is Discovery’s collaboration partner *Clinical and physical activity habits must be sustained for rest of life to achieve this reduction in mortality 𝑥 = 𝑎𝑔𝑒 𝑦 = 𝑙𝑖𝑓𝑒𝑠𝑡𝑦𝑙𝑒 𝑎𝑛𝑑 𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 ℎ𝑎𝑏𝑖𝑡𝑠 𝑢𝑝 𝑡𝑜 𝑎𝑔𝑒 𝑥, 𝑎𝑛𝑑 𝑠𝑡𝑎𝑡𝑒 𝑜𝑓 ℎ𝑒𝑎𝑙𝑡ℎ 𝑎𝑡 𝑎𝑔𝑒 𝑥 𝑧 = 𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑛𝑒𝑤 𝑙𝑖𝑓𝑒𝑠𝑡𝑦𝑙𝑒 𝑎𝑛𝑑 𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 ℎ𝑎𝑏𝑖𝑡𝑠 𝑓𝑟𝑜𝑚 𝑎𝑔𝑒 𝑥 𝑜𝑛𝑤𝑎𝑟𝑑𝑠 QUICK to implement 3-month deployment into new markets Redeployable modules EFFICIENT to operate Standardised process & once-off builds to link partners, upgrade products, enhance features across the board EASY to configure Cloud based Multi-language Scalable -- 66 of 75 -- 67 VHI -- 67 of 75 -- 68 Vitality Health International 1 2 3 USA Leveraged the Group's data and assets to enhance its product offerings and expand its market share in the US Excellent pre-tax operating profit growth Expanded reach into 6 countries Maiden dividend to shareholders Taken action to ensure strong business fundamentals Improved operating ratio Increased diversification Reduced investment income volatility 5 healthcare cost-saving products deployed in 6 Asia-Pacific markets Major product upgrade nearing completion Progress in sales to US health plans, a key strategic segment Products span across the entire value chain of health insurance Vitality USA has built an integrated digital health & care experience Strong operating result with reduction in combined ratio, strong cash generation & maiden shareholder dividend 30% of CY 2023 distributable profits R255 million DSY’s share after withholding tax Note: Quantium Health, which is part of VHI, has not been included in this update Systems Data & Analytics Risk management Digital engagement Other Claims Benefit mgmt. Risk profile Clinical encoder Vitality CDM PMI product Network etc. Provider mgmt. FWA etc. Vitality 3.0 Regional Blue Cross Blue Shield plan, and largest provider- sponsored health plan in state -- 68 of 75 -- 69 -- 69 of 75 -- 70 Ping An Health Insurance PAHI’s operating results pre-tax Discovery’s operating result after tax PAHI licence new business1 Written premium1 +56% +82% +12% +15% to RMB2.1bn (RMB 0.5bn DSY’s share) to RMB434m to RMB3.8bn to RMB22.6bn Lives +26% to 27.4m PAHI licence lives +59% +85% +14% +17% to R5.4bn (R .4bn DSY’s share) to R1 124m to R9.9bn to R58.6bn 1 100% of PAHI 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 Reinsurance PAHI licence 2020 2021 2022 2023 2024 Jun-20 Dec-20 Jun-21 Dec-21 Jun-22 Dec-22 Jun-23 Dec-23 Jun-24 RMB millions RMB millions RMB millions RMB millions -- 70 of 75 -- 71 Strong business fundamentals after years of focus on building a quality specialist health insurer Improved operating ratio Reduced investment income volatility Increased diversification All figures are for the period 1 January – 30 June for the corresponding year, unless otherwise stated • Restructured agent commissions, reducing costs and improving tax efficiency • Improved risk management, lowering loss ratio; o Strengthened claims risk management o Enhanced underwriting o Upgraded non-disclosure systems • Revised investment return target for a more conservative asset allocation • Reduced equity exposure • Focused on assets yielding non-taxable returns • Revamped SuiShenYi • Partnered with flagship third-party brokerages • Launched tailored products across affordability and healthcare needs • Targeted products for channels like Douyin, Mingya and Ant Combined ratio 50% 70% 90% 110% 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 Investment income and gains Profit before investment income and gains PAHI’s operating result pre-tax 79 58 21 42 2023 2024 Non-eShengBao eShengBao 74 71 26 29 2023 2024 Non-PAL PAL Channels Products Investable assets (RMB m, as at 30 June) 19,869 23,328 2023 2024 +17% -- 71 of 75 -- 72 Maintained robust balance sheet 1 For the period 1 January – 30 June for the corresponding year 2 As at 30 June for the corresponding year Cashflows from operating activities1 Retained earnings2 First dividend paid to shareholders Comprehensive SCR2 30% of CY 2023 distributable profits R255 million Discovery’s share after withholding tax Jun-23 Jun-24 1,949 1,778 +10% RMB million RMB million Jun-23 Jun-24 3,079 4,247 +38% Jun-23 Jun-24 267% 320% RMB3.27bn for 12 months Jun 23 – Jul 24 -- 72 of 75 -- 73 In summary 1 Strong FY24 performance 2 Entering a new phase in the lifecycle of the Group 3 Normalised operating profit +17% New business +18% FLR 20% Cash conversion 66% Scaling of the Vitality Shared- value Insurance model Enabling Discovery Bank as composite maker for SA Earnings growth 15-20% % spend on New c5% Cash conversion 60-70% RoE 15-20% Creating two distinct businesses with significant ambition and a common business model FLR 10-20% Dividend <5x -- 73 of 75 -- 74 Presentation Disclaimer This presentation has been prepared based of the Discovery Group’s reviewed condensed consolidated financial information for the year ended 30 June 2024 and the notes to the condensed consolidated financial statements have been reviewed by our independent joint auditors, Deloitte & Touche and KPMG Inc. who expressed an unmodified review conclusion. The review report does not necessarily report on all information contained in these financial results. This presentation may contain forward looking statements with respect to certain of Discovery’s plans and its current goals and expectations relating to its future performance and results. All forward looking statements involve risk and uncertainty because they relate to future events and circumstances which are beyond Discovery’s control. Accordingly, Discovery’s actual future financial performance and results may differ. Any reference to future financial performance has not been audited or reported on by the Group’s auditors. -- 74 of 75 -- Annual Results Presentation for the year ended 30 June 2024 -- 75 of 75 --